News

Parexel Biotech and RenovoRx Reach Key Milestone in Pancreatic Cancer Clinical Trial for Locally-Advanced Pancreatic Cancer

January 13, 2020

TIGeR-PaC Phase III trial reaches first patient in Europe, with overall enrollment exceeding 20 percent worldwide Los Altos, Calif., Boston, Durham, N.C.– Jan. 13, 2020 – RenovoRx, Inc., an innovator in…

RenovoRx Announces Issuance of Fifth U.S. Patent

January 8, 2020

Phase III Clinical Trial for Pancreatic Cancer Patients Currently Enrolling Los Altos, CA, January 8, 2020 – RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent…

Contemporary Management of Pancreatic Cancer

October 1, 2019

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies. Reviews how recent advances in surgery, radiation therapy, ablative options, and…

Woman Receiving Experimental Treatments For Pancreatic Cancer At UPMC *

July 15, 2019

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.

New Cancer Procedure Gifts Bay Area Couple 3 More Years Together *

May 2, 2019

Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.

All About Cancer with Dr. Ripal Gandhi, Dr. Raj Narayanan, Dr. Horacio Asbun

November 28, 2018

The Baptist Health South Studios presents with Dr. Ripal Gandhi, Dr. Raj Narayanan and Dr. Horacio Asbun the state of pancreatic cancer for the patient and treatment options available.

RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer

May 23, 2018

Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach. LOS ALTOS, Calif. – May 23, 2018 – RenovoRx, Inc., a medical technology company developing…

Researchers Report Survival Benefits with Use of RenovoCath™ in Patients with Locally Advanced Pancreatic Tumors

April 19, 2017

LOS ALTOS, CA – RenovoRx, a Silicon Valley-based medical device company, announced today that two teams of researchers treating patients with advanced non-metastatic pancreatic tumors reported beneficial effects including lengthened…

Presentation of Data on Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Loco-regional Pancreatic Tumors

April 2, 2017

Aim: A dose escalation study of Gemcitabine for treatment of unresectable pancreatic cancer, using a targeted intra-arterial delivery catheter (RenovoCath™). Methods: 20 patients at two centers were enrolled with a…

RenovoRx Announces FDA Clearance for Expanded Labeling

March 30, 2017

LOS ALTOS, Calif., March 30, 2017 /PRNewswire/ — RenovoRx, manufacturer of the RenovoCath adjustable dualballoon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for…

* Individual results may vary.

News

Delivering Therapy Where it Matters™